Loading...
•
Dec 31, 2024
Dynavax Q4 2024 Earnings Report
Dynavax reported its fourth quarter and full year 2024 financial results, highlighting record HEPLISAV-B product revenue and advancements in its pipeline programs.
Key Takeaways
Dynavax achieved record HEPLISAV-B product revenue in 2024 and continued to advance its pipeline programs. The company reported a 30% increase in total revenues for Q4 2024 compared to Q4 2023, and a significant increase in adjusted EBITDA year-over-year.
HEPLISAV-B net product revenue for Q4 2024 increased by 39% year-over-year to $71.1 million.
Total revenues for Q4 2024 were $72.0 million, a 30% increase from the prior year.
GAAP net income for Q4 2024 was $7.1 million, or $0.06 per share (basic).
Adjusted EBITDA for Q4 2024 increased by 225% year-over-year to $13.4 million.
Revenue by Segment
Forward Guidance
For the full year 2025, Dynavax expects HEPLISAV-B net product revenue to be between $305 million and $325 million, and Adjusted EBITDA to be at least $75 million.
Positive Outlook
- Expected HEPLISAV-B net product revenue in the range of $305 million to $325 million for 2025.
- Anticipated Adjusted EBITDA of at least $75 million for 2025.
- Top-line results from Phase 1/2 shingles trial expected in Q3 2025.
- Plan to initiate Phase 2 trial for plague vaccine in Q3 2025.
- Expect completion of $200 million share repurchase program in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...